-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Pyrotinib is an original targeted drug independently developed by a Chinese pharmaceutical company with intellectual property rights
.
The reporter learned on the 25th that the research results of pyrotinib combined with capecitabine in the treatment of brain metastases from HER2-positive breast cancer were published online in the international authoritative medical journal "Lancet Oncology"
.
.
The reporter learned on the 25th that the research results of pyrotinib combined with capecitabine in the treatment of brain metastases from HER2-positive breast cancer were published online in the international authoritative medical journal "Lancet Oncology"
.
The results of a multi-center study led by Professor Yan Min from Henan Cancer Hospital showed that pyrotinib combined with capecitabine was well tolerated and could effectively inhibit both intracranial and extracranial lesions, especially in patients with previously untreated brain metastases.
Benefit is obvious
.
This study will bring new insights into the clinical treatment of breast cancer brain metastases and individualized decision-making
.
Benefit is obvious
.
This study will bring new insights into the clinical treatment of breast cancer brain metastases and individualized decision-making
.
It is reported that the current treatment of brain metastases is mainly based on local treatment methods, including surgical resection, stereotactic radiotherapy and whole brain radiotherapy
.
However, the recurrence rate within 6-12 months after local treatment is still high, and it will bring adverse reactions such as cognitive decline , which brings great challenges to clinical treatment
.
.
However, the recurrence rate within 6-12 months after local treatment is still high, and it will bring adverse reactions such as cognitive decline , which brings great challenges to clinical treatment
.
Prof.
Yan Min told reporters: "The treatment of breast cancer in China must be based on the disease development characteristics of the Chinese population and the status of clinical diagnosis and treatment to guide clinical practice
.
This is the initiation of China's independent research and development of innovative drugs pyrotinib combined with capecitabine in the treatment of HER2-positive breast cancer brains.
The most important significance of the transfer phase II clinical study
.
"
Yan Min told reporters: "The treatment of breast cancer in China must be based on the disease development characteristics of the Chinese population and the status of clinical diagnosis and treatment to guide clinical practice
.
This is the initiation of China's independent research and development of innovative drugs pyrotinib combined with capecitabine in the treatment of HER2-positive breast cancer brains.
The most important significance of the transfer phase II clinical study
.
"
Yan Min introduced that according to the research results, for HER2-positive breast cancer brain metastases, pyrotinib combined with capecitabine can effectively control both intracranial and extracranial lesions
.
Pyrotinib is expected to become the preferred treatment for HER2-positive brain metastases in China
.
.
Pyrotinib is expected to become the preferred treatment for HER2-positive brain metastases in China
.
Pyrotinib is an original targeted drug independently developed by a Chinese pharmaceutical company, Hengrui Medicine , with intellectual property rights
.
In 2018, Pyrotinib was approved by the National Medical Products Administration (NMPA) with conditions for its Phase II clinical study data
.
According to reports, at present, pyrotinib is still conducting a number of clinical studies covering breast cancer, lung cancer, biliary tract cancer and other tumor types, and continues to explore treatment options for different diseases at different stages, benefiting more Chinese patients
.
(Finish)
.
In 2018, Pyrotinib was approved by the National Medical Products Administration (NMPA) with conditions for its Phase II clinical study data
.
According to reports, at present, pyrotinib is still conducting a number of clinical studies covering breast cancer, lung cancer, biliary tract cancer and other tumor types, and continues to explore treatment options for different diseases at different stages, benefiting more Chinese patients
.
(Finish)
Pyrotinib is an original targeted drug independently developed by a Chinese pharmaceutical company with intellectual property rights
.
The reporter learned on the 25th that the research results of pyrotinib combined with capecitabine in the treatment of brain metastases from HER2-positive breast cancer were published online in the international authoritative medical journal "Lancet Oncology"
.
.
The reporter learned on the 25th that the research results of pyrotinib combined with capecitabine in the treatment of brain metastases from HER2-positive breast cancer were published online in the international authoritative medical journal "Lancet Oncology"
.
The results of a multi-center study led by Professor Yan Min from Henan Cancer Hospital showed that pyrotinib combined with capecitabine was well tolerated and could effectively inhibit both intracranial and extracranial lesions, especially in patients with previously untreated brain metastases.
Benefit is obvious
.
This study will bring new insights into the clinical treatment of breast cancer brain metastases and individualized decision-making
.
Benefit is obvious
.
This study will bring new insights into the clinical treatment of breast cancer brain metastases and individualized decision-making
.
It is reported that the current treatment of brain metastases is mainly based on local treatment methods, including surgical resection, stereotactic radiotherapy and whole brain radiotherapy
.
However, the recurrence rate within 6-12 months after local treatment is still high, and it will bring adverse reactions such as cognitive decline , which brings great challenges to clinical treatment
.
.
However, the recurrence rate within 6-12 months after local treatment is still high, and it will bring adverse reactions such as cognitive decline , which brings great challenges to clinical treatment
.
Prof.
Yan Min told reporters: "The treatment of breast cancer in China must be based on the disease development characteristics of the Chinese population and the status of clinical diagnosis and treatment to guide clinical practice
.
This is the initiation of China's independent research and development of innovative drugs pyrotinib combined with capecitabine in the treatment of HER2-positive breast cancer brains.
The most important significance of the transfer phase II clinical study
.
"
Yan Min told reporters: "The treatment of breast cancer in China must be based on the disease development characteristics of the Chinese population and the status of clinical diagnosis and treatment to guide clinical practice
.
This is the initiation of China's independent research and development of innovative drugs pyrotinib combined with capecitabine in the treatment of HER2-positive breast cancer brains.
The most important significance of the transfer phase II clinical study
.
"
Yan Min introduced that according to the research results, for HER2-positive breast cancer brain metastases, pyrotinib combined with capecitabine can effectively control both intracranial and extracranial lesions
.
Pyrotinib is expected to become the preferred treatment for HER2-positive brain metastases in China
.
.
Pyrotinib is expected to become the preferred treatment for HER2-positive brain metastases in China
.
Pyrotinib is an original targeted drug independently developed by a Chinese pharmaceutical company, Hengrui Medicine , with intellectual property rights
.
In 2018, Pyrotinib was approved by the National Medical Products Administration (NMPA) with conditions for its Phase II clinical study data
.
According to reports, at present, pyrotinib is still conducting a number of clinical studies covering breast cancer, lung cancer, biliary tract cancer and other tumor types, and continues to explore treatment options for different diseases at different stages, benefiting more Chinese patients
.
(Finish)
.
In 2018, Pyrotinib was approved by the National Medical Products Administration (NMPA) with conditions for its Phase II clinical study data
.
According to reports, at present, pyrotinib is still conducting a number of clinical studies covering breast cancer, lung cancer, biliary tract cancer and other tumor types, and continues to explore treatment options for different diseases at different stages, benefiting more Chinese patients
.
(Finish)
Pyrotinib is an original targeted drug independently developed by a Chinese pharmaceutical company with intellectual property rights
.
The reporter learned on the 25th that the research results of pyrotinib combined with capecitabine in the treatment of brain metastases from HER2-positive breast cancer were published online in the international authoritative medical journal "Lancet Oncology"
.
.
The reporter learned on the 25th that the research results of pyrotinib combined with capecitabine in the treatment of brain metastases from HER2-positive breast cancer were published online in the international authoritative medical journal "Lancet Oncology"
.
The results of a multi-center study led by Professor Yan Min from Henan Cancer Hospital showed that pyrotinib combined with capecitabine was well tolerated and could effectively inhibit both intracranial and extracranial lesions, especially in patients with previously untreated brain metastases.
Benefit is obvious
.
This study will bring new insights into the clinical treatment of breast cancer brain metastases and individualized decision-making
.
Cancer Hospital Cancer Cancer Hospital HospitalBenefit is obvious
.
This study will bring new insights into the clinical treatment of breast cancer brain metastases and individualized decision-making
.
It is reported that the current treatment of brain metastases is mainly based on local treatment methods, including surgical resection, stereotactic radiotherapy and whole brain radiotherapy
.
However, the recurrence rate within 6-12 months after local treatment is still high, and it will bring adverse reactions such as cognitive decline , which brings great challenges to clinical treatment
.
adverse reaction adverse reaction.
However, the recurrence rate within 6-12 months after local treatment is still high, and it will bring adverse reactions such as cognitive decline , which brings great challenges to clinical treatment
.
Prof.
Yan Min told reporters: "The treatment of breast cancer in China must be based on the disease development characteristics of the Chinese population and the status of clinical diagnosis and treatment to guide clinical practice
.
This is the initiation of China's independent research and development of innovative drugs pyrotinib combined with capecitabine in the treatment of HER2-positive breast cancer brains.
The most important significance of the transfer phase II clinical study
.
"
disease disease diseaseYan Min told reporters: "The treatment of breast cancer in China must be based on the disease development characteristics of the Chinese population and the status of clinical diagnosis and treatment to guide clinical practice
.
This is the initiation of China's independent research and development of innovative drugs pyrotinib combined with capecitabine in the treatment of HER2-positive breast cancer brains.
The most important significance of the transfer phase II clinical study
.
"
Yan Min introduced that according to the research results, for HER2-positive breast cancer brain metastases, pyrotinib combined with capecitabine can effectively control both intracranial and extracranial lesions
.
Pyrotinib is expected to become the preferred treatment for HER2-positive brain metastases in China
.
.
Pyrotinib is expected to become the preferred treatment for HER2-positive brain metastases in China
.
Pyrotinib is an original targeted drug independently developed by a Chinese pharmaceutical company, Hengrui Medicine , with intellectual property rights
.
In 2018, Pyrotinib was approved by the National Medical Products Administration (NMPA) with conditions for its Phase II clinical study data
.
According to reports, at present, pyrotinib is still conducting a number of clinical studies covering breast cancer, lung cancer, biliary tract cancer and other tumor types, and continues to explore treatment options for different diseases at different stages, benefiting more Chinese patients
.
(Finish)
medicine medicine medicine .
In 2018, Pyrotinib was approved by the National Medical Products Administration (NMPA) with conditions for its Phase II clinical study data
.
According to reports, at present, pyrotinib is still conducting a number of clinical studies covering breast cancer, lung cancer, biliary tract cancer and other tumor types, and continues to explore treatment options for different diseases at different stages, benefiting more Chinese patients
.
(Finish)
